While there is now a multitude of potent medications for relapsing-remitting multiple sclerosis (RRMS), effective therapies targeting neurodegeneration in progressive multiple sclerosis types are still lacking. Stimulation of neurorepair in this disease remains a pathogenetically defined treatment goal. However, therapeutic progress is slowed by the still inadequate tool set to capture “regeneration/repair” in MS and to define appropriate outcomes in clinical trials.
Objectives:
In this review, we discuss studies investigating promising regenerative agents for progressive MS which were recently presented during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)/Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 meeting in Paris.
HauserSLBar-OrAComiGet al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
4.
MontalbanXHauserSLKapposLet al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
5.
SedelFBernardDMockDMet al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology2016; 110(Pt B): 644–653.
6.
TourbahALebrun-FrenayCEdanGet al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler2016; 22(13): 1719–1731.
7.
WakitaHTomimotoHAkiguchiIet al. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res2003; 992(1): 53–59.
8.
SuzumuraAItoAYoshikawaMet al. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res1999; 837(1–2): 203–212.
9.
CammerWZhangH.Maturation of oligodendrocytes is more sensitive to TNF alpha than is survival of precursors and immature oligodendrocytes. J Neuroimmunol1999; 97(1–2): 37–42.
10.
NakazawaTNakazawaCMatsubaraAet al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci2006; 26(49): 12633–12641.
11.
Kagitani-ShimonoKMohriIFujitaniYet al. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation2005; 2(1): 10.
12.
BarkhofFHulstHEDrulovicJet al. Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?Neurology2010; 74(13): 1033–1040.
13.
FoxRJCoffeyCSCudkowiczMEet al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials2016; 50: 166–177.
14.
MeiFFancySPJShenYAet al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med2014; 20(8): 954–960.
15.
MeiFLehmann-HornKShenYAet al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife2016; 5: e18246.
16.
GreenAJGelfandJMCreeBAet al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial. Lancet2017; 390(10111): 2481–2489.
17.
KüryPNathACréangeAet al. Human endogenous retroviruses in neurological diseases. Trends in Molecular Medicine2018. Epub ahead of print March152018. DOI: 10.1016/j.molmed.2018.02.007.
18.
PerronHJouvin-MarcheEMichelMet al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology2001; 287(2): 321–332.
19.
RollandAJouvin-MarcheESaresellaMet al. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis. J Neuroimmunol2005; 160(1–2): 195–203.
20.
PerronHDougier-ReynaudHLLomparskiCet al. Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS One2013; 8(12): e80128.
21.
KremerDSchichelTForsterMet al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol2013; 74(5): 721–732.
22.
WolinskyJS.Patient selection for trials. Mult Scler2017; 23(12): 1636–1641.
23.
KremerDGottlePHartungHPet al. Pushing forward: Remyelination as the new frontier in CNS diseases. Trends Neurosci2016; 39(4): 246–263.
24.
StangelMKuhlmannTMatthewsPMet al. Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nat Rev Neurol2017; 13(12): 742–754.
25.
KremerDAktasOHartungHPet al. The complex world of oligodendroglial differentiation inhibitors. Ann Neurol2011; 69(4): 602–618.
